Company news

Roche Holding Ltd news in 2026

Roche Holding Ltd's news releases, calls and decks from 2026, newest first.

View company

Genentech’s Divarasib Demonstrated Best-in-Class Efficacy, Advancing the Standard of Care in Previously Treated KRAS G12C-mutated Lung Cancer

October 25, 2026

Genentech Presents Interim Phase III Data Showing Sefaxersen Significantly Reduced Proteinuria in People With IgA Nephropathy (IgAN)

October 23, 2026

Genentech Presents New Pivotal Trial Data Across Broad Neuroimmunology Portfolio at MSToronto2026

October 21, 2026

Genentech to Present Pivotal Data at ESMO 2026, Showcasing Advances Across Its Lung and Breast Cancer Late-Stage Portfolio

October 19, 2026

FDA Approves Genentech’s Enspryng, a First-in-Class IL-6R Inhibitor, as the First and Only At-Home Subcutaneous Treatment Option for Thyroid Eye Disease (TED)

October 16, 2026

Genentech Presents New Phase III One-Year Data for Vamikibart in Uveitic Macular Edema (UME), a Serious Cause of Vision Loss

October 10, 2026

Genentech Presents New Data at EURETINA, Highlighting Vabysmo’s Real-World Effectiveness and Safety Across Major Retinal Conditions

October 1, 2026

Roche fenebrutinib is the first BTK inhibitor to receive U.S. FDA filing acceptance in both relapsing and primary progressive multiple sclerosis

September 30, 2026

Roche launches newborn screening test for three severe genetic conditions

September 30, 2026

Genentech Breaks Ground on $750 Million Manufacturing Expansion in Hillsboro, Oregon

September 28, 2026

Positive Interim Data Shows Genentech’s Sefaxersen Significantly Reduces Proteinuria in People With IgA Nephropathy (IgAN)

September 23, 2026

Genentech Announces Positive Phase II Results for Dual GLP-1/GIP Receptor Agonist Enicepatide in People Living With Type 2 Diabetes and Overweight or Obesity

September 22, 2026

European Commission approves Roche’s Susvimo® for the treatment of neovascular age-related macular degeneration (nAMD)

September 21, 2026

CHMP recommends EU approval of Roche’s Ocrevus for children and adolescents with relapsing multiple sclerosis

September 18, 2026

Genentech and Roche Announce Grand Opening of Boston R&D Innovation Center

September 17, 2026

Genentech’s Lunsumio-Based Regimen Significantly Improves Progression-Free Survival in Follicular Lymphoma in Phase III CELESTIMO Study

September 17, 2026

U.S. FDA grants Priority Review for Roche’s Enspryng for MOGAD, an autoimmune disease with no approved treatments

September 10, 2026

Roche receives FDA approval for companion diagnostic tests to identify patients with HER2-positive metastatic gastroesophageal adenocarcinoma eligible for ZIIHERA

August 26, 2026

Roche receives FDA clearance for Elecsys® pTau217, advancing Alzheimer's disease assessment across primary and specialty care

August 24, 2026

Genentech Announces Manufacturing Expansion in Hillsboro, Oregon

August 20, 2026

Genentech Marks Topping out Milestone for New Holly Springs, North Carolina Manufacturing Facility

August 18, 2026

Roche receives FDA clearance for the cobas® BV/CV assay, enabling fast and highly accurate vaginitis diagnosis

July 24, 2026

Roche showcases intelligent lab solutions and high-precision instruments at ADLM 2026 to help laboratories address workforce and workflow challenges

July 22, 2026

Roche Appoints Dan Malarek as President and CEO of Roche Diagnostics North America

July 20, 2026

FDA Grants Priority Review to Genentech’s Gazyva for Adults With Primary Membranous Nephropathy

July 15, 2026

Roche receives CE Mark for blood test to identify tuberculosis infection

July 9, 2026

Roche presents new data in Alzheimer’s disease from across its integrated pharmaceutical and diagnostics portfolio at AAIC

July 7, 2026

Genentech and Roche Present New Data in Alzheimer’s Disease From Across Its Integrated Pharmaceutical and Diagnostics Portfolio at AAIC

July 7, 2026

[Ad hoc announcement pursuant to Art. 53 LR] Roche’s divarasib shows superiority in head-to-head phase III trial against approved KRAS G12C inhibitors in non-small cell lung cancer

July 2, 2026

FDA grants Priority Review to Roche's Enspryng, the first and only at-home subcutaneous treatment option for thyroid eye disease (TED)

June 30, 2026

FDA Accepts Supplemental Biologics License Application for Genentech’s Lunsumio and Polivy Combination for People With Relapsed or Refractory Large B-Cell Lymphoma

June 18, 2026

Roche receives FDA approval for the first companion diagnostic to assess PTEN protein in people living with prostate cancer

June 12, 2026

Roche's VENTANA MMR RxDx Panel companion diagnostic receives IVDR approval across multiple cancer types and therapies

June 11, 2026

FDA grants Priority Review for Roche’s Tecentriq for a certain type of stage III colon cancer

June 11, 2026

Roche rapidly develops a PCR test for Ebola within six days as rare Bundibugyo virus drives urgent need for detection

June 4, 2026

FDA accepts New Drug Application for Roche’s giredestrant in ER-positive early-stage breast cancer, the first and only oral SERD with positive phase III results in the curative setting

June 2, 2026

Genentech to Present New Data Advancing Its Obesity Portfolio at the American Diabetes Association’s 2026 Scientific Sessions

June 1, 2026

Roche launches the Liver Disease Panel, the first suite of certified algorithms to support Chronic Liver Disease management

May 27, 2026

Genentech to Present New Data at ASCO 2026, Reinforcing Giredestrant's Potential to Transform the Treatment Paradigm in Early Breast Cancer

May 19, 2026

FDA Approves Genentech’s Tecentriq for Adjuvant Muscle-Invasive Bladder Cancer With ctDNA-Guided Treatment

May 15, 2026

Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217)

May 12, 2026

Roche enters into a definitive merger agreement to acquire PathAI to transform AI-driven diagnostics

May 7, 2026

Roche to present extensive data showcasing its industry-leading ophthalmology portfolio at ARVO 2026

April 30, 2026

Zealand Pharma and Roche to advance petrelintide, an amylin analog, to Phase 3 trials for chronic weight management

April 29, 2026

Genentech Partners With Comedy Icon Damon Wayans and diaTribe to Address Diabetes-Related Vision Loss With ‘All Eyes on DME’ Campaign

April 24, 2026

[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong sales growth of +6% at constant exchange rates in the first quarter of 2026; -5% in CHF due to the significant appreciation of the Swiss franc

April 23, 2026

Roche's ENSPRYNG (satralizumab) reduces risk of relapses by 68% demonstrating potential to become first treatment for MOGAD

April 22, 2026

Roche’s fenebrutinib significantly reduced relapses versus standard of care to approximately one every 17 years in RMS

April 21, 2026

Roche’s ENSPRYNG (satralizumab) reduces risk of relapses by 68% demonstrating potential to become first treatment for MOGAD

April 21, 2026

FDA accepts application for Roche’s Gazyva/Gazyvaro for the treatment of the most common form of lupus

April 21, 2026

Older news releases →

Calls in 2026

Decks in 2026